Anlotinib, a novel multi-targeted tyrosine kinase inhibitor used as an anti-angiogenic agent for treating a variety of tumors, is reported to inhibit angiogenesis in GBM by inhibiting the JAK2/STAT3/VEGFA signaling pathways and inducing autophagy in GBM cells by increasing Beclin-1 and microtubule-associated protein 1 light chain 3B (LC3B). Here, STAT3 is linked to glioblastoma.